Position
Squarepoint Ops LLC in Akebia Therapeutics, Inc.
Back to the book · All holders of AKBA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$93K$1.61 → $1.39
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.22M | $1.97M | — | — | — | 0.0% |
| Q1 2026 | 422.8K | $587.7K | $1.39 | −$93K | −$1.29M | 0.0% |